Evaluating a new injection for female contraception without estrogen
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION - UTAH
This study is testing a new long-lasting birth control shot called levonorgestrel butanoate, especially for women who are overweight and may have a higher risk of blood clots, to see if it’s a safer and easier option than daily pills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11041792 on NIH RePORTER |
What this research studies
This research investigates a new long-acting injectable contraceptive called levonorgestrel butanoate (LB), designed specifically for women, particularly those who are obese and at risk for venous thromboembolism (VTE). The study aims to provide an easier-to-follow contraceptive option compared to traditional progestin-only pills, which require strict daily adherence. By focusing on an estrogen-free formulation, the research seeks to enhance safety and efficacy in contraception for women who may be at higher risk due to their weight. Participants will be involved in a clinical trial to assess the effectiveness and safety of this new contraceptive method.
Who could benefit from this research
Good fit: Ideal candidates for this research are women, particularly those who are obese and seeking effective contraception without the risks associated with estrogen.
Not a fit: Patients who are not seeking contraception or those who do not have concerns related to VTE may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more convenient contraceptive option for women, especially those at risk for VTE.
How similar studies have performed: Previous research has shown success with other long-acting contraceptive methods, but this specific formulation is novel and aims to address a unique patient population.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Turok, David — University of Utah
- Study coordinator: Turok, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.